Jacqualyn A. Fouse is Director at AGIOS PHARMACEUTICALS, INC. (AGIO). They have made 8 open-market trades across 2 companies since 2011, most recently 2026-06-18.
CIK 0001405288
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $1.7M since 2011, against 1 sale. Across 7 scored buys the stock is up 6.7% at ninety days, and 5.3 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 14% | 100% | 100% |
| Avg Move | -10.8% | +4.3% | +6.7% |
| Alpha | -6.0% | +3.8% | +5.3% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AGIO | SELL · 10b5-1 | 2025-04-10 | 2025-04-10 | $25.90 | $388K | +11.2% | +14.2% | +53.1% |
| AGIO | SELL · 10b5-1 | 2024-04-10 | 2024-04-10 | $27.55 | $429K | -0.6% | +8.6% | +40.5% |
| AGIO | SELL · 10b5-1 | 2024-01-24 | 2024-01-24 | $21.64 | $464K | +9.0% | +51.5% | +46.1% |
| AGIO | SELL · 10b5-1 | 2024-01-09 | 2024-01-09 | $22.99 | $386K | -9.9% | +0.8% | +15.5% |
| AGIO | SELL | 2023-06-30 | 2023-06-30 | $28.36 | $608K | -0.6% | -5.7% | -11.9% |
| AGIO | BUY | 2019-11-13 | 2019-11-15 | $31.00 | $1.2M | +7.2% | +26.1% | +42.8% |
| CELG | BUY | 2012-05-21 | 2012-05-21 | $68.92 | $69K | -13.8% | +0.7% | +0.7% |
| CELG | BUY | 2011-11-01 | 2011-11-28 | $63.92 | $64K | -13.8% | +0.7% | +0.7% |
| CELG | BUY | 2011-08-09 | 2011-08-09 | $54.13 | $54K | -13.8% | +0.7% | +0.7% |
| CELG | BUY | 2011-08-05 | 2011-08-08 | $55.75 | $56K | -13.8% | +0.7% | +0.7% |
| CELG | BUY | 2011-08-01 | 2011-08-02 | $59.47 | $119K | -13.8% | +0.7% | +0.7% |
| CELG | BUY | 2011-06-14 | 2011-06-14 | $58.26 | $117K | -13.8% | +0.7% | +0.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Total |
| $27.8M |
Shares reported on the most recent Form 4, priced at the 2026-06-23 close.